Web29 de ene. de 2010 · Dr. Heather Wakelee, MD, is a specialist in medical oncology who treats patients in Palo Alto, CA. This provider has 27 years of experience and is affiliated with Stanford Hospital. They accept 53 insurance plans. Web1 de may. de 2024 · Heather Wakelee, MD: Associate Professor of Medicine, Stanford Cancer Institute, Stanford, California. Dr. Wakelee was the late Dr. Paul Kalanithi's treating oncologist. Dr. Wakelee noted that she did not participate in the Kalanithis discussion about having a child and did not think that the family should have consulted her.
Dr. Heather Wakelee, MD Palo Alto, CA Medical Oncology - Vitals
Web28 de oct. de 2024 · Dr. Heather Wakelee thoracic medical oncologist and professor of medicine at Stanford University Medical Center and president-elect of IASLC and … Web11 de mar. de 2015 · The relationship between a patient and an oncologist needs to be a very open one, says oncologist Heather Wakelee, associate professor of oncology at the Stanford University Medical Center. "It's important that it's a partnership," she says. In her own practice, she welcomes and encourages patient input into their own care. introduce a friend to bt
Dr. Wakelee on Detection of EGFR T790M Mutation in NSCLC
WebDr. Heather Wakelee, MD is a medical oncology specialist in Palo Alto, CA. ... She coordinates with my local oncologist without a hitch. — May 03, 2024. See more reviews on Healthgrades. How would you rate your experience with … WebOncologist. 2024 Jul;22(7):786-796. doi: 10.1634/theoncologist.2016-0458. Epub 2024 May 9. Authors Christina S Baik 1 , Nathaniel J Myall 2 , Heather A Wakelee 2 Affiliations 1 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, USA [email protected]. 2 Stanford University Medical Center, Palo Alto ... Web13 de may. de 2024 · Role of Immunotherapy in Stage III Unresectable NSCLC May 13, 2024 Jessica A. Hellyer, MD, and Heather A. Wakelee, MD Author Bios Disclosures Article Highlights Immune checkpoint inhibitors (ICIs) have greatly changed the landscape for patients with unresectable stage III non–small cell lung cancer. new model sears